Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALIBRATE
2026-525547-32-01Phase 4Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Sep 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in coronary arteriosclerosis, Chronic Coronary Syndrome (CCS) and atherosclerosis comparing Colchicine with Placebo (2 arms). Primary endpoint: Change in arterial inflammation in carotid arteries. Planned start Sep 2026; status: authorised.
02
Drugs
colchicine
03
Conditions
coronary arteriosclerosisChronic Coronary Syndrome (CCS)atherosclerosis
Beyond the preview
Go deeper on 2026-525547-32-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525547-32-01.